Loading…
Phathom Pharmaceuticals, Inc. is projected to rise to $11.44 by 2027, a +7% move from its current price of $10.74. PHAT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.40 | $10.74 | $11.09 | -0.01% |
| May 30 | $10.27 | $10.74 | $11.23 | -0.02% |
| May 31 | $10.16 | $10.74 | $11.34 | -0.03% |
| Jun 1 | $10.07 | $10.74 | $11.44 | -0.04% |
| Jun 2 | $10.00 | $10.73 | $11.53 | -0.05% |
| Jun 3 | $9.93 | $10.73 | $11.60 | -0.06% |
| Jun 4 | $9.87 | $10.73 | $11.67 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.87 | $10.73 | $11.67 | -0.07% |
| Week 2 | $9.52 | $10.72 | $12.08 | -0.14% |
| Week 3 | $9.26 | $10.72 | $12.40 | -0.21% |
| Week 4 | $9.05 | $10.71 | $12.67 | -0.28% |
| Week 5 | $8.87 | $10.70 | $12.92 | -0.35% |
| Week 6 | $8.70 | $10.69 | $13.14 | -0.42% |
| Week 7 | $8.55 | $10.69 | $13.35 | -0.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases in the United States.
It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc. (PHAT) operates in the Healthcare sector as an asset named Phathom Pharmaceuticals, Inc.
The stock currently trades at $11.33 and has a market capitalization of $903.63M. It is ranked 2610.
The overall price outlook is informed by a multi-year forecast, which includes a 2026 average of $11.33 and shows progression to higher averages in later years, with a 2050 max of $112.80.
Key long-term forecast milestones include a 2027 avg of $12.13, a 2030 avg of $18.01, and a 2050 max of $112.80, illustrating a potential equity upside over time.
A major floor 16.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 25.4% above — a clean break opens room to run.
A major ceiling 33.9% above — clearing it would confirm fresh momentum.
Key PHAT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PHAT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.32 | Sell | $11.21 | Sell |
| MA 10 | $11.69 | Sell | $11.52 | Sell |
| MA 20 | $11.96 | Sell | $11.77 | Sell |
| MA 50 | $11.77 | Sell | $11.96 | Sell |
| MA 100 | $12.41 | Sell | $12.22 | Sell |
| MA 200 | $12.85 | Sell | $11.99 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.33 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -152.67 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -11.68 | Sell |
| Bollinger %B (20,2) | 0.01 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.04 | Sell |
| Awesome (5,34) | -0.83 | Sell |
| Ultimate (7,14,28) | 27.49 | Buy |
| Momentum (10) | -1.79 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 10.98 | Sell |
| ADX (14) | 12.87 | Neutral |
| ATR (14) | 0.36 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 40.
The 50-day simple moving average is $11.75 and the 200-day simple moving average is $12.83.
Near-term support sits at $11.20 and resistance at $13.47. The 30-day trading range spans $9.12 to $14.07. The annualized volatility is 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.06 | $10.74 | $13.25 | 0% | Neutral | |
| $8.93 | $11.44 | $15.61 | +7% | Neutral | |
| $10.02 | $13.26 | $18.84 | +23% | Bullish | |
| $10.93 | $14.86 | $21.80 | +38% | Bullish | |
| $12.07 | $16.82 | $25.35 | +57% | Bullish | |
| $11.76 | $16.74 | $25.84 | +56% | Bullish | |
| $11.10 | $16.13 | $25.43 | +50% | Bullish | |
| $11.38 | $16.87 | $27.11 | +57% | Bullish | |
| $12.57 | $18.99 | $31.05 | +77% | Bullish | |
| $15.03 | $23.12 | $38.43 | +115% | Bullish | |
| $16.08 | $26.84 | $47.76 | +150% | Bullish | |
| $27.58 | $53.23 | $104.54 | +396% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $10.06 | $10.74 | $12.57 | +0.00% |
| June 2026 | $8.92 | $10.52 | $12.72 | -2.09% |
| July 2026 | $8.94 | $10.64 | $13.07 | +1.20% |
| August 2026 | $8.60 | $10.31 | $12.82 | -3.10% |
| September 2026 | $8.25 | $9.95 | $12.49 | -3.47% |
| October 2026 | $8.44 | $10.24 | $12.97 | +2.90% |
| November 2026 | $8.63 | $10.53 | $13.44 | +2.80% |
| December 2026 | $8.41 | $10.31 | $13.25 | -2.07% |
Click any year to see its month-by-month PHAT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PHAT could reach as high as $13.25, with a base case around $10.74 and support toward $10.06 — roughly 0% from $10.74. Price action looks broadly range-bound.
Expect PHAT to range from $8.93 to $15.61 through 2027. The $11.44 average target implies a +7% move from current prices. That is up +7% on the projected 2026 average. A consolidation phase looks the most probable path here.
The PHAT price prediction for 2028 points to an average of $13.26 (low $10.02, high $18.84) — a potential gain of +23% on today's $10.74. Momentum favours further upside here.
In 2029, PHAT is projected to trade between $10.93 and $21.80, averaging $14.86 — a potential gain of +38% from today's $10.74. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Phathom Pharmaceuticals, Inc.'s 2030 outlook centres on $16.82, within a $12.07 to $25.35 range. That is up +13% on the projected 2029 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2031, PHAT could reach as high as $25.84, with a base case around $16.74 and support toward $11.76 — roughly +56% from $10.74. Buyers look set to stay in control over this stretch.
Expect PHAT to range from $11.10 to $25.43 through 2032. The $16.13 average target implies a +50% move from current prices. That is -4% versus the projected 2031 average. Momentum favours further upside here.
The PHAT price prediction for 2033 points to an average of $16.87 (low $11.38, high $27.11) — a potential gain of +57% on today's $10.74. Buyers look set to stay in control over this stretch.
In 2034, PHAT is projected to trade between $12.57 and $31.05, averaging $18.99 — a potential gain of +77% from today's $10.74. That is up +13% on the projected 2033 average. Momentum favours further upside here.
Phathom Pharmaceuticals, Inc.'s 2035 outlook centres on $23.12, within a $15.03 to $38.43 range. That is up +22% on the projected 2034 average. That marks a +115% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, PHAT could reach as high as $47.76, with a base case around $26.84 and support toward $16.08 — roughly +150% from $10.74. Momentum favours further upside here.
Expect PHAT to range from $27.58 to $104.54 through 2050. The $53.23 average target implies a +396% move from current prices. That is up +98% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PHAT today (≈ 93.10987 PHAT) could be worth
$4,955.87
+$3,955.87 (+396%) by 2050 · US Dollar
Based on the average projected PHAT price of $53.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PHATwould be worth at today's price.
$1,000 invested in PHAT on May 27, 2025 (≈ 242.718453 PHAT) would be worth
$2,606.8
+$1,606.8 (+160.7%) today · 2.61× · US Dollar
Based on a PHAT entry price of $4.12 vs. today's $10.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.87 | $904.8 | -9.5% |
| 1 month ago | $11.59 | $926.66 | -7.3% |
| 3 months ago | $13.56 | $792.04 | -20.8% |
| 6 months ago | $15.62 | $687.58 | -31.2% |
| 1 year ago | $4.12 | $2,606.8 | +160.7% |
| All time (5.0y) ago | $35.91 | $299.08 | -70.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PHAT forecast.
Our base-case forecast reaches $21.00 around 2035.
Implied market cap at $21.00: $1.67B
The multi-year forecast shows a bullish trajectory across multiple years, with the 2026–2035 period posting rising averages and positive price momentum. For example, the 2030 average is $18.01 with a 59% ROI, and the 2040 average is $28.45 with a 151.1% ROI. By 2050, the average is forecast at $56.68 with a 400.3% ROI.
Other notable points include: 2027 average $12.13 (7.1% ROI), 2028 average $14.09 (24.3% ROI), 2029 average $15.73 (38.9% ROI), 2031 average $17.75 (56.7% ROI), 2033 average $18.06 (59.4% ROI), and 2035 average $24.57 (116.8% ROI).
These are estimates, not guarantees, and actual results can differ due to a range of factors.
Tap a question to reveal the answer.
Avg $18.01; min $12.84; max $27.36; ROI 59%; sentiment BULLISH.
The forecast shows a bullish long-term trajectory with rising averages and positive ROIs (e.g., 2029 ROI 38.9%, 2030 ROI 59%, 2050 ROI 400.3%), but these are estimates, not guarantees.
In 2040 the max forecast is $51.20, so reaching around $50 is within the forecast.
Current price $11.33; market cap $903.63M.
Avg $12.13; min $9.43; max $16.65; ROI 7.1%; sentiment NEUTRAL.
Phathom Pharmaceuticals, Inc. Community Discussion
0Share your Phathom Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.